Terminated PHASE2 INTERVENTIONAL 4-arm NCT04493216

A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults (DOMINO)

A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults

Sponsor: ViiV Healthcare

Conditions HIV Infections

Interventions ABC/3TC Dolutegravir FTC/TAF GSK3640254 Placebo

Updated 23 times since 2020 Last updated: May 29, 2024 Started: Nov 18, 2020 Primary completion: Sep 5, 2022 Completion: May 29, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Company decision to stop compound development. The decision is not based on any safety or efficacy concerns. It reflects the company strategy for portfolio progression.

Other terminated trials from ViiV Healthcare

See all terminations from ViiV Healthcare

Other HIV Infections trials with similar outcome

Browse all HIV Infections trials

Listed as NCT04493216, this PHASE2 trial focuses on HIV Infections and remains terminated or withdrawn. Sponsored by ViiV Healthcare, it has been updated 23 times since 2020, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

23 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2023 — Jul 2024 [monthly]

Terminated PHASE2

Status: Active Not Recruiting → Terminated
Feb 2023 — Dec 2023 [monthly]

Active Not Recruiting PHASE2

▶ Show 18 earlier versions

Jan 2023 — Feb 2023 [monthly]

Active Not Recruiting PHASE2
Nov 2022 — Jan 2023 [monthly]

Active Not Recruiting PHASE2
Sep 2022 — Nov 2022 [monthly]

Active Not Recruiting PHASE2
Jul 2022 — Sep 2022 [monthly]

Active Not Recruiting PHASE2
Jun 2022 — Jul 2022 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Apr 2022 — Jun 2022 [monthly]

Recruiting PHASE2
Jan 2022 — Apr 2022 [monthly]

Recruiting PHASE2
Dec 2021 — Jan 2022 [monthly]

Recruiting PHASE2
Nov 2021 — Dec 2021 [monthly]

Recruiting PHASE2
Sep 2021 — Nov 2021 [monthly]

Recruiting PHASE2
May 2021 — Sep 2021 [monthly]

Recruiting PHASE2
Apr 2021 — May 2021 [monthly]

Recruiting PHASE2
Mar 2021 — Apr 2021 [monthly]

Recruiting PHASE2
Feb 2021 — Mar 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2021 — Feb 2021 [monthly]

Not Yet Recruiting PHASE2
Nov 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2
Oct 2020 — Nov 2020 [monthly]

Not Yet Recruiting PHASE2
Aug 2020 — Oct 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ViiV Healthcare

Data source: ViiV Healthcare

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Alicante, Spain , Almada, Portugal , Aveiro, Portugal , Badalona, Barcelona, Spain , Barcelona, Spain , Berkley, United States , Bochum, Germany , Brescia, Italy , Buenos Aires, Argentina and 39 more locations